CRL Earnings
Latest Revenue1.0B
Latest Net Income-760000
| Period | EPS | Revenue | Net Income | Rev YoY | EPS YoY |
|---|
| Q2 2026 | -$0.03 | 1.0B | -760000 | -2.7% | -102.8% |
| Q1 2026 | -$0.30 | 995.8M | -14802000 | +1.2% | -160.0% |
| Q4 2025 | -$5.62 | 994.2M | -276290000 | -0.8% | -33.2% |
| Q3 2025 | $1.11 | 1.0B | 55.6M | -0.5% | -17.2% |
| Q2 2025 | $1.06 | 1.0B | 52.7M | +0.6% | -39.4% |
| Q1 2025 | $0.50 | 984.2M | 25.9M | -2.7% | -61.8% |
| Q4 2024 | -$4.22 | 1.0B | -213747000 | -1.1% | -215.6% |
| Q3 2024 | $1.34 | 1.0B | 70.3M | -1.6% | -21.2% |
| Q2 2024 | $1.75 | 1.0B | 94.3M | — | — |
| Q1 2024 | $1.31 | 1.0B | 74.5M | — | — |
| Q4 2023 | $3.65 | 1.0B | 189.0M | — | — |
| Q3 2023 | $1.70 | 1.0B | 88.0M | — | — |
Charles River Laboratories International (CRL) — Earnings